Literature DB >> 25622214

A web-based study of the relationship of duration of insulin pump infusion set use and fasting blood glucose level in adults with type 1 diabetes.

Alysa J Sampson Perrin1, Russell C Guzzetta, Kellee M Miller, Nicole C Foster, Anna Lee, Joyce M Lee, Jennifer M Block, Roy W Beck.   

Abstract

BACKGROUND: To evaluate the impact of infusion set use duration on glycemic control, we conducted an Internet-based study using the T1D Exchange's online patient community, Glu ( myGlu.org ). SUBJECTS AND METHODS: For 14 days, 243 electronically consented adults with type 1 diabetes (T1D) entered online that day's fasting blood glucose (FBG) level, the prior day's total daily insulin (TDI) dose, and whether the infusion set was changed.
RESULTS: Mean duration of infusion set use was 3.0 days. Mean FBG level was higher with each successive day of infusion set use, increasing from 126 mg/dL on Day 1 to 133 mg/dL on Day 3 to 147 mg/dL on Day 5 (P<0.001). TDI dose did not vary with increased duration of infusion set use.
CONCLUSIONS: Internet-based data collection was used to rapidly conduct the study at low cost. The results indicate that FBG levels increase with each additional day of insulin pump infusion set use.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25622214     DOI: 10.1089/dia.2014.0336

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  7 in total

Review 1.  Moving Toward a Unified Platform for Insulin Delivery and Sensing of Inputs Relevant to an Artificial Pancreas.

Authors:  Anneke Graf; Sybil A McAuley; Catriona Sims; Johanna Ulloa; Alicia J Jenkins; Gayane Voskanyan; David N O'Neal
Journal:  J Diabetes Sci Technol       Date:  2016-12-13

2.  Tissue Response to Subcutaneous Infusion Catheter.

Authors:  Ershuai Zhang; Zhiqiang Cao
Journal:  J Diabetes Sci Technol       Date:  2019-03-31

3.  Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes.

Authors:  Andrew W Karlin; Trang T Ly; Laura Pyle; Gregory P Forlenza; Laurel Messer; R Paul Wadwa; Daniel J DeSalvo; Sydney L Payne; Sarah Hanes; Paula Clinton; David M Maahs; Bruce Buckingham
Journal:  Diabetes Technol Ther       Date:  2016-05-26       Impact factor: 6.118

4.  Using Insulin Infusion Sets in CSII for Longer Than the Recommended Usage Time Leads to a High Risk for Adverse Events: Results From a Prospective Randomized Crossover Study.

Authors:  Andreas Pfützner; Daniela Sachsenheimer; Marco Grenningloh; Matthias Heschel; Lene Walther-Johannesen; Rabi Gharabli; David Klonoff
Journal:  J Diabetes Sci Technol       Date:  2015-09-03

5.  Glycemic Control and Factors Impacting Treatment Choice in Tubeless Insulin Pump Users: A Survey of the T1D Exchange Glu Online Community.

Authors:  Jennifer E Layne; Lauren M Huyett; Trang T Ly
Journal:  J Diabetes Sci Technol       Date:  2019-08-13

6.  Systematic in vivo evaluation of the time-dependent inflammatory response to steel and Teflon insulin infusion catheters.

Authors:  Jasmin R Hauzenberger; Julia Münzker; Petra Kotzbeck; Martin Asslaber; Vladimir Bubalo; Jeffrey I Joseph; Thomas R Pieber
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

7.  Skin-Related Complications Among Adolescents With Type 1 Diabetes Using Insulin Pump Therapy.

Authors:  Ayman A Al Hayek; Asirvatham A Robert; Mohamed A Al Dawish
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2018-09-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.